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ABSTRACT: An apparatus was designed to mimic lactation from a human breast. It was used to determine the influence of milk fat content
and flow rate, and suction pulse rate of a breastfeeding infant upon the release of a model compound from a nipple shield delivery system
(NSDS). The NSDS would be worn by a mother to deliver drugs and nutrients to her infant during breastfeeding. Sulforhodamine B dye
(SB) was used as model compound and formulated as a dispersible tablet to be placed within the NSDS. Increasing suction pulse rate
from 30 to 120 pulses/min clearly correlated with increased cumulative release of SB for the same volume of milk passed through the
NSDS. No distinct correlation was found between flow rates (1, 5, and 8 mL/min) and SB release, possibly because of competing factors
controlling release rate at different flow rates. A highly similar SB release rate into two fat content fluids (2.9 and 4.2 wt %) was observed
for identical flow conditions. This proof of concept study outlines a novel method to mimic lactation from a breast, and future studies will
lead to effective methods to identify key physiological factors that influence drug release from a NSDS. C© 2013 Wiley Periodicals, Inc. and
the American Pharmacists Association J Pharm Sci 102:3773–3783, 2013
Keywords: Controlled release/delivery; drug delivery systems; in vitro models; lactation; nipple shield delivery system; oral drug delivery;
pediatric
INTRODUCTION
Difficulties in Infant Drug Delivery
New drug delivery systems are urgently needed for the treat-
ment of pediatric diseases, especially in developing countries.1,2
Each year more than 7.6 million children under 5 years die
worldwide from diseases that could often have been prevented
if they had access to appropriate forms of simple and afford-
able medicines.3 Liquid formulations are typically the princi-
pal method for pediatric drug administration, but are often
not practical in developing countries because of sterility issues,
high cost, lack of access to refrigeration, and limited shelf life.4–6
They may also be unpalatable and contain toxic preservatives
and solvents. Solid oral dosage forms for infants are also often
scaled down from adult doses, and there is currently a debate
on the limitations of clinical work performed to demonstrate
suitability of the dose to infant.7,8 Dispersible tablets can also
be used, but require sterile sources of water and administration
devices.
Nipple Shield Delivery System
This paper outlines the development of experimental research
to guide the design of a recently proposed novel drug and nu-
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trient delivery system intended to be used for breastfeeding
infants—a nipple shield delivery system (NSDS).9,10 This thin
disposable device adapted from an existing nipple shield breast-
feeding aid is placed over the mother’s breast just before infant
feeding, and when milk passes through the device it releases
the agent to be delivered to the infant via the breast milk. A
wide-range of active pharmaceutical ingredients (APIs) could
be delivered to infants using the NSDS such as antibiotics,
antivirals, antimalarials, vitamins, nutrients, and probiotics
while stored in a dry form. The NSDS has the potential to re-
move many of the issues related to maintaining sterility and
stability of drugs delivered to infants in developing countries.
The NSDS would most likely be in a single-use form for
low-resource settings, as there may be difficulties in ensuring
sterile repeat use. The device will have to be designed to ensure
dosage is attained well within all typical feeding behaviors. Fu-
ture clinical studies will determine the most appropriate device
design and technique for effective use to ensure no disruption
to the infant’s normal breastfeeding behavior. A color indicator,
which is only apparent once a critical dose has been delivered,
could be contained within the NSDS for the mother to identify
when the critical dosage has been achieved.
Previously, the effective delivery of the anti-HIV microbi-
cide sodium dodecyl sulfate from a nonwoven NSDS insert into
simulated breastfeeding fluid flow conditions, as well as sub-
sequent inactivation of HIV, has been demonstrated.10 The po-
tential of antiviral polycationic coatings in a NSDS for use in
inactivating the free virus from milk has also been examined.11
In the present study, the delivery of a model drugmimic from
a tablet placed within the NSDS has been examined using an
apparatus that simulates the fluid dynamics of breastfeeding.
To our knowledge, there are no previously published details
of an apparatus of this form, that mimics the suction of the
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infant, and the lactation of milk from a human nipple induced
because of this suction. The influence of an infant’s tongue dur-
ing breastfeeding is also an important element to consider and
is described in the discussion.
Physiological Factors Influencing Tablet Release from a NSDS
Many physiological factors vary during breastfeeding and be-
tween infants and their mothers that may influence the rate
of delivery of a therapeutic from a NSDS to the feeding infant
(i.e., they influence the dynamic behavior of milk contacting a
NSDS tablet containing the drug). These include nipple size
and duct structure,12 feeding behavior allowed by the mother,
suction pulse rate of the infant, flow of milk out of the breast,13
and importantly the potential changes in feeding behavior of
the infant in response to foreign tasting agents from the NSDS
(which may support the addition of taste-masking excipients to
increase acceptability).
This study focuses on the influence of fat content and flow
rate of milk, and the suction pulse rate of the infant, three
factors known to vary significantly between infants and during
a single breastfeed.
Changes in Fat Composition
Human milk’s main constituents are fat (triacylglycerol lipid
globules with a phospholipid–protein membrane), protein (ca-
seins and whey—including enzymes and immunoglobulins),
and several forms of carbohydrates (primarily lactose).14–16 The
fat content in breast milk has been reported to increase up
to threefold within a feed with typical ranges between 2 and
6wt%.17,18 Studies byKhan et al.19,20 that collected the foremilk
and hindmilk (the beginning and end of a breastfeed) from
human breastfeeding also observed a significant increase in
fat content between samples collected from individual donors,
but no statistically different change in either protein (casein,
whey, and skim milk) or lactose content during a feed. Also,
within a single day, the average fat composition of milk has
been shown to vary significantly depending on infant feeding
behavior, whereas protein and lactose contents remained sta-
ble. It is also important to note that significant variations in
milk contents between individual infant-mother pairs may oc-
cur at the same stage postpartum.20 Over the first 30 days of
life, the average total protein and lactose content significantly
decreases and fat content increases, after which time all three
compositions remain relatively stable.21–24
Suction Rate of Infant
Typical suction rates in breastfeeding upon the onset of nutri-
tive sucking (i.e., significant flows of milk leaving the breast)
have been reported to range typically between 40 and 120 suc-
tion pulses/min, although this can vary depending on the
stage of the feed and infant.13,25,26 A typical feed volume has
been shown to be approximately 50 –80 g ingested over 7 –
10 min.18,27,28
Flow Rates of Milk from Breast
Flow rate also significantly changes depending on the infant
and the phase of the feed. A previous review of breastfeeding
behavior reports that volumes of milk intake can vary signifi-
cantly between 0.01 and 0.14mL/suction pulse, whichwhen cor-
related against suction pulse rates of 40–120 pulses/min gives
potential average flow rates of 0.4 –16.8 mL/min.13
Study Aims
The present proof of concept study investigated the effect of
typically reported values of milk fat content and flow rate,
and infant suction rate in breastfeeding upon the delivery of
a model compound in a tablet placed inside an NSDS. This was
performed using an apparatus that simulates the pressure con-
ditions, average flow rate, fluid motion, and composition of milk
as it leaves a nipple and passes through a NSDS.
MATERIALS AND METHODS
Adapting Nipple Shields to Contain Tablets
Nipple shield delivery system prototypes were made by adapt-
ing an existing commercial nipple shield to hold a tablet. A
nipple shield (Maternity Silicone Nipple Shields, Boots, Cam-
bridge, UK) had a 15-mm outer diameter O-ring (3.9 mm thick,
9.5 mm inner diameter) with a fiberglass mesh (1.4 mm square
spacing with 0.4 mm fiber diameter) sealed inside the nipple
shield using silicone (Platsil Gel 00, Mouldlife, Suffolk, UK) at
9 mm from the inside tip of the nipple. The mesh was placed on
the side of the O-ring nearest to the inside of the nipple shield in
order to allow a tablet to sit within the O-ring in the shield. This
allowed tablets to be accurately positioned in the same location
for experiments. The nipple shield had four evenly spaced 1mm
holes around the nipple to allow milk to pass out of the device.
An additional eight evenly spaced holes of the same diameter to
the existing holes were added 5 mm further down the nipple to
increase the release of the disintegrated tablet from the device
(see Fig. 1). Preliminary experiments indicated that without
these additional holes a build up of fragmented tablet within
the shield reservoir occurred.
NSDS Tablets Used
Round-faced tablets (0.33 g, 8 mm diameter) were formu-
lated by direct compression using a Manesty F3 tablet press
(Manesty, Liverpool, UK) and a biconcave punch and die set
(Holland, Nottingham, UK) with a crushing strength of 80 N.
A dispersible formulation was used to maximize the likelihood
of API delivery well within a typical breastfeed (up to ∼80 g).18
Sulforhodamine B (SB) (Sigma–Aldrich, Dorset, UK), a highly
soluble red dye monosodium salt, was used as a model API. The
dye was found to be accurately detected in milk using a spec-
troscopic assay without additional samplemanipulation, with a
peak absorbance at 554 nm. Tablet excipients used were based
on typical pharmaceutical requirements for a fast disintegrat-
ing tablet using direct compression.29 Tables 1 and 2 outline the
composition, excipient role, and the results of standard Euro-
pean Pharmacopeia physical testing performed on the tablets.
Simulation of Milk Flow from a Human Nipple
A silicone human nipple mimic (HNM) was constructed with
ducts to simulate the flow of milk leaving a breast induced from
an infant’s suction. The silicone nipple shape was formed out of
a polyurethane mold from epoxy modeling board (constructed
using a computer-aided design high-pressure waterjet). This
produced a hemisphere with a 12-mm diameter based on a typi-
cal size of a nipple.12 A square grid of 25 equally spaced stainless
steel needles held apart using a plastic mesh was also placed
into the mold when the silicone (Platsil Gel 00; Mouldlife) was
poured in. The needle number, size, and spacing were based on
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Figure 1. Nipple shield and tablet type used in experiments. (a) Modified nipple shield containing tablet holder O-ring. (b) Close up of modified
nipple shield with additional holes added to promote milk and tablet release from shield reservoir (indicated by arrows). (c) Tablet positioned
inside nipple shield O-ring holder.
Table 1. Formulation of Tablets Used in All Experiments
Chemical Role w/w Grade Manufacturer
Sulforhodamine B Model compound 2.6 75% Purity Sigma–Aldrich, Dorset, UK
Lactose (SuperTabR© 14SD) Filler 91.4 Ph. Eur DFE Pharma, Goch, Germany
Sodium starch glycolate (ExplotabR© CLV) Superdisintegrant 3.0 Typ (A) Ph. Eur Mendell GmbH, Vo¨lklingen, Germany
Croscarmellose sodium (Ac-Di-Sol) Superdisintegrant 2.0 Ph. Eur FMC Biopolymer, Girvan, UK
Magnesium stearate Lubricant 1.0 Technical grade Sigma–Aldrich, Dorset, UK
Table 2. Physical Characteristics of Tablets Used in Experimentation (European Pharmacopeia Methods)
Mean Weight
[(mg) ± SD]
Mean Crushing Strength
[(N) ± SD]
Tensile Strength
[(MPa) ± SD]
Friability
[(%) ± SD]
Disintegration Time
(Water at 37◦C)
[(min, s) ± SD (s)]
n = 20 n = 5 n = 5 n = 20 n = 6
329 ± 1 76.8 ± 1.9 1.06 ± 0.03 0.3 ± 0.03 1 min 56 s ± 4.16
mimicking pore dimensions from previously reported analysis
of dissected nipples.12 After the silicone had set, the needles
were carefully pushed through the outside of the nipple to cre-
ate flow channels through it and then were removed leaving 25
evenly spaced pores passing through the HNM. The nipple was
then attached using silicone to an oval silicone shape to allow
the nipple shield to seal well around the nipple (see Fig. 2).
Human Milk Used in Experimentation
Anonymized human milk samples were obtained from approx-
imately 20 healthy donors from the Queen Charlotte’s and
ChelseaHospitalMilk Bank (Imperial CollegeHealthcare NHS
Trust). The donors had all consented for their milk to be used
for research as it was not able to be used for donation. They
were screened for HIV 1 and 2, HTLV I and II, hepatitis B and
Figure 2. Diagram and dimensions of silicone human nipple mimic (HNM) and positioning relative to the nipple shield for release tests. (Right)
Nipple shield with tablet positioned on the HNM. The HNM is sealed using silicone within an oval silicone shape to allow the nipple shield to seal
well and maintain pressure conditions. (Left) Cross-section and front view of HNM with 25 evenly square spaced ducts. All indicated measured
lengths are in mm; diagram is not to scale.
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C, and syphilis, and ethical approval for use was obtained from
the University of Cambridge (Cambridge Human Biology Re-
search Ethics Committee, University of Cambridge). Approx-
imately 5 L of milk from 10 donors was pooled into a sin-
gle composition, aliquoted into 50 mL centrifuge tubes and
stored at −80◦C. The remaining milk from separate donors
(also ∼ 5 L) was also pooled into a single composition, and then
half was placed in 50 mL centrifuge tubes and centrifuged at
5411 g (5500 RPM) using a Sigma 3 –16 PK centrifuge (Sigma–
Zentrifugen, Osterode, Germany) for 15 min. A fat layer ob-
tained at the top of the flask was then carefully removed using
a curved face spatula, and the remaining milk was pooled into
a single flask. After centrifugation, a small pellet (<0.25 mL)
was also observed at the bottom of the tubes (presumed to be
predominantly protein) and using a pipette was resuspended
in 5 mL of the fat-free milk and added to the main flask. This
fat-free milk and the milk not centrifuged were then combined
at different proportions to make up several mixtures with dif-
ferent fat compositions. Samples were then placed in 50 mL
centrifuge tubes and stored at −80◦C.
The test milk samples were measured for total fat and pro-
tein content. Fat content was measured using a creamatocrit
method. Briefly, 1 mL samples were placed in 4.6 mm inner
diameter 80 mm length transparent thick walled plastic tubes
and centrifuged at 920 g using a Sigma 3 –16 PK centrifuge
(Sigma–Zentrifugen) for 15 min. Creamatocrit is defined as the
percentage of the upper fat length formed in centrifugation
to the total length of the liquid in the tube. Using Wang et
al.’s30 correlation of creamatocrit to fat content in human milk
samples previously frozen the approximate fat content was es-
timated. Wang et al.’s30 correlation is for samples stored and
thawed from −20◦C rather than −80◦C, but is still thought
to give a reasonable indication of content. Total protein con-
tent was determined using a standard Bradford Agent (Sigma–
Aldrich) assay.31 All measurements were performed in tripli-
cate on triplicate samples and the average taken.
Quantification of SB in Milk
The absorbances at 554 nm of 230 :L calibration solutions of
API mimic SB were measured in triplicate in flat-bottomed 96-
well plates (Sterilin, Newport, UK) for each milk type using
an EnVision 2104 Multilabel Platereader, (PerkinElmer, Cam-
bridgeshire, UK). Lines of best fit using a power law were used
for all fluids apart from the skimmed (fat free) milk where a
polynomial fit was used. R2 values for all fits were at least
of 0.99. Concentrations were found to be accurately detected
between approximately 1 × 10−4 and 0.1 wt % for all fluids.
Typically within 5% of all SB was accounted for in preliminary
dissolution tests using humanmilk, indicating that the possible
interference of tablet excipients upon SB detection was within
acceptable limits for this proof of concept study.
Experimental Apparatus Design and Operation
Release experiments were conducted using an apparatus out-
lined in Figure 3. The system operated by continuously stirred
human milk in a reservoir (Supplementary Information, S1)
being steadily pumped using a peristaltic pump (P1) (Master-
flex model 7521–35; easy-load II model 77200–60; Cole-Palmer,
London, UK) into the HNM. Prior to reaching the HNM, the
milk was also heated (using a heat-exchanger HX1) so as to exit
the HNM at 37◦C. Attached to the HNM was the nipple shield
Figure 3. Nipple shield breastfeeding simulation apparatus and de-
scriptions of apparatus components and valve status during apparatus
operation.
containing the SB tablet. Milk was drawn out of the HNM us-
ing a vacuum pump (P3). It then passed through the nipple
shield and tablet and now containing the disintegrated tablet
fractions was pumped using a peristaltic pump (P2) (Master-
flex model 7521–75, easy-load model 7518–10, Cole-Palmer) to
a fraction collector (FC1) (SuperFracTM fraction collector; GE
Healthcare Sciences, Buckinghamshire, UK), and the collected
fractions were assayed for SB content.
The HNM and nipple shield were securely held together us-
ing a customized clamp to ensure they were located in the same
position for each experiment. They were also at the same an-
gle for all experiments (30◦ down from the vertical). The clamp
ensured the system was airtight. The positioning of the nip-
ple shield over the HNM allowed approximately a 1-mm gap
between the tip of the HNM and the tablet. A silicone-sealed
funnel (S3) on the outside of the nipple shield was connected
via an air line to the vacuum pump (P3).
The vacuum pump induced a regular wave-like pressure cy-
cle, which upon its increase in vacuum drew milk out of the
HNM onto the tablet. During the release of suction pressure,
no milk left the HNM (as previously reported in physiological
environments),27 and the feed pump (P1) continuously loaded
the HNM with more milk to be drawn out of the nipple for the
next suction cycle. The purpose of the feed pump was to dictate
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the mean flow rate of fluid throughout experiments, whereas
the vacuum pump controlled the withdrawal of milk from the
HNM. Preliminary experiments demonstrated that without the
feed pump (P1) the flow rate from the milk reservoir could not
be accurately controlled (unpublished data).
Also attached to the lower part of the funnel (S3) connected
to the nipple shield was a small reservoir that collected the fluid
as it left the nipple shield. The reservoir had a pipe attached
to its base that was connected to the peristaltic pump (P2),
which drew the fluid out of the reservoir. It also maintained the
vacuum within the system, effectively acting as a nonreturn
valve. The fluid then passed to the fraction collector FC1 that
collected fluid in approximately 1.0–1.5 mL fractions. Because
the system was constantly under vacuum, preliminary testing
using a nonreturn valve instead of the pump P2 did not allow
fluid to be released out of the system without a significant build
up of fluid behind the valve. The speed of P2 was adjusted
to match the average flow rate of fluid entering the reservoir
(dictated by P1) so as to not influence the vacuum pressure
within the system.
The vacuum pump (P3) was amodifiedMedela swing electric
breast pump (Medela, Manchester, UK). The pump’s control cir-
cuitry was connected to a National Instruments (NI) controller
(NI 9401 8 Ch; 5 V/TTL High-Speed Bidirectional Digital I/O
Module; National Instruments, Austin, Texas) and controlled
by a National Instruments 2011 Labview software (via a NI
CompactDAQ 4-Slot USB Chassis) on a Microsoft Windows XP
computer. This was used to control the suction rate, depth of
suction, and pattern of suction of the pumpwith amuch greater
range of control than the pump’s originalmanual controls. Pres-
sure within the nipple shield was measured using a SSOB002A
pressure gauge (PS) (Sensortechnics, Munich, Germany). The
pressure readings were also displayed and logged using the
Labview program via a National Instruments data acquisition
unit (NI USB-6008 12-Bit, 10 kS/s Multifunction DAQ).
The pressure patterns induced could also be controlled by
a manual needle control valve (CV1) (Swagelok, Hertfordshire,
UK), which could change themean pressure (i.e., what the pres-
sure waves cycled around). By opening CV1, the mean vacuum
pressure decreased closer to atmospheric pressure. Also a 50
mL syringe (S4) was connected to the air line system which
could control the amplitude of the pressure waves induced -
opening the syringe increased the air volume in the system
and subsequently reduced the amplitude of the cyclic suction
pulses.
The system allowed a constant vacuum to be held between
suction cycles based on breastfeeding behavior,27 which was
not possible using the unmodified breast pump. Figure 4a
compares typical pressure profiles induced by the unmodified
breast pump and the modified pump (used in experiments) pro-
ducing a suction profile typical of a breastfeeding infant.27 For
experiments, the pressure cycle was kept constant for the entire
test in order to strengthen attribution of drug release behavior
to a particular variable; however, in a physiological setting, the
pressure profile of suction throughout is complex, with changes
in amplitude, mean pressure, and suction rate.27,28,32
At the beginning of experiments, milk was drawn into a
20-mL reservoir (S2) where 3 mL was allowed to build up.
This reservoir dampened the pulsed flow pattern induced by
the feed pump (P1). The vacuum pump (P3) and exit reservoir
pump (P2) were then turned on and the feed reservoir valve
(V3) was opened. Fluid passed out of the feed reservoir through
Figure 4. Pressure profiles produced within the breastfeeding sim-
ulation apparatus comparing: (a) two pressure profiles induced by
an unmodified breast pump at limits of operation (setting 1: maxi-
mum frequency and minimum suction; setting 2: minimum frequency
and maximum suction), and an example of the modified breast pump
profile based on typical pressure profiles of a baby’s suction during
breastfeeding27 and (b) examples of typical pressure profiles used in
experiments for suction pulses of 30, 60, and 120 suction pulses/min.
a nonreturn valve into the HNM. The nonreturn valve pre-
vented fluid being forced back into the feed reservoir during
the increased pressure step of the vacuum pump cycle.
Experiment Test Sets
Three experimental test sets were performed, each varying one
factor known to change in breastfeeding while keeping all other
conditions constant. These factors were pulse rate, flow rate,
and milk fat content. Where one condition was varied, all other
conditions were kept constant at previous typically reported
physiological conditions.
Approximately 50 mL of human milk was used for each ex-
periment and experiments were performed in triplicate. For
pulse and flow rate experiments, the same pooled milk was
used, whereas as previously discussed for fat content tests, sep-
arate pooled milk was used with the fat content varied by fat
removal using centrifugation. Table 3 outlines the conditions
used for all experiments.
Four different suction pulse rates of 120, 60, 30, and
0 pulses/min were investigated using an average flow rate of
5 mL/min. The same amplitude of suction was also used for
all conditions. For 0 suction pulses/min, the feed pump (P1)
dictated the flow profile leaving the HNM—this condition was
used as a control to investigate the influence of pulsed behavior
of fluid produced by P3 versus constant flow rate induced by P1
on SB release from the tablet. Figure 4b displays the typical
pressure profiles induced in the nipple shield for suction pulse
rates of 120, 60, and 30 suction pulses/min.
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Table 3. Test Conditions for All Experiments
Fluid Composition
Figure Displaying Experiments
and Data Symbols
Avg. Flow Rate
(mL/min)
Pulse Rate
(pulse/min)
Mean Pressure
(mm Hg)
Average Amplitude
(mm Hg)
Fat
(%)
Creamatocrit
(wt %)a
Protein
(wt %)
5  5 120 −105 35 5.5 3.4 2.1
 5 60 −105 35 5.5 3.4 2.1
 5 30 −105 35 5.5 3.4 2.1
 5 0 0 0 5.5 3.4 2.1
6  8 60 −105 35 5.5 3.4 2.1
 5 60 −105 35 5.5 3.4 2.1
 1 60 −105 35 5.5 3.4 2.1
7  5 60 −105 35 7.1 4.2 1.7
◦ 5 60 −105 35 4.6 2.9 1.7
 5 60 −105 35 0.0 0.0 1.2
aBased on previously reported correlation of creamatocrit to fat content in human milk.30
For flow-rate experiments, three average flows of 1, 5, and
8 mL/min were used, while under a constant suction pulse rate
of 60 pulses/min at constant amplitude and mean pressure.
For fat content experiments, three compositions were con-
sidered. One content reflecting a typical average fat content
of milk (4.2 wt %), another reflecting a lower (2.9 wt %) con-
tent that is found in foremilk17,18, and finally one where the fat
had been removed, which is not found in physiological circum-
stances but was used to gain further insight on the potential
influence of fat in a breastfeed. For all fluids, the average flow
rate was kept constant at 5 mL/min and suction pulse rate con-
stant at 60 pulses/min with a constant amplitude and mean
pressure.
RESULTS
For all tests, milk was seen to fill the reservoir of the nip-
ple shield before releasing in pulsed bursts into the collection
reservoir (S3) in sync with the increasing vacuum phase in-
duced by P3. After tests, thin patches of insoluble white solid
were found adhered to the inside of the nipple shield, presumed
to be tablet excipient. Soaking the nipple shield in 3.5 M sul-
furic acid (Sigma–Aldrich) at 70◦C for 3 h was found to remove
this coating without causing degradation to the nipple shield.
Results are graphically presented as the average of triplicate
tests for each test condition used, with error bars representing
the standard error between repeat tests. Data points at 1.5 mL
intervals are displayed on results graphs, which are the aver-
age of the linear interpolation between sample points for each
test. Results were compared using a one-way ANOVA analysis
(posttest: Newman–Keuls multiple comparison test, software:
GraphPad Prism 5, GraphPad Software, Inc., La Jolla, Califor-
nia) with significance at (*) p < 0.05, (**) p < 0.01, and (***)
p < 0.001, indicated on the result graphs below the data points
(Figs. 5, 6, 7). The experimental procedure described in this
manuscript is an adapted dissolution test for a standard tablet
formulation. ANOVA is commonly used in comparative analy-
sis for such studies33, so was deemed acceptable for this work.
Results are displayed as the average release of SB as a func-
tion of volume for: (1) wt % in collected fractions; and (2) the
cumulative mass of SB relative to the initial amount of SB in
the tablet.
Varying Suction Pulse Rate
Figure 5 displays SB release for suction pulse rates of 120, 60,
30 pulses/min and constant flow (0 pulses/min) with the aver-
age flow rate for all four conditions at 5 mL/min. Before 18 mL,
suction pulse rates of 30, 60, and 120 pulses/min produced
similar release patterns, and after 24 mL, there was a trend
of higher suction pulse rate correlating with higher average
cumulative release. After 6mL, posttest analysis demonstrated
that a suction pulse rate of 0 pulses/min had a significantly
lower cumulative release than all other conditions for the en-
tire test. Suction pulse rate tests of 60 and 30 pulses/min were
not significantly different from each other for the majority of
testing for both cumulative release and individual wt % frac-
tions.
Varying Flow Rate
Figure 6 displays SB release for flow rates of 1, 5, and 8mL/min
at a constant suction pulse rate of 60 pulses/min. Pulse
amplitude and average vacuum pressure were also kept the
same for all flow rates. At the flow rate of 8 mL/min, data were
only available for the three repeat tests up to 40mL. Therewere
no clear trends in release concentration or cumulative release
among the three flow rates. After 3 mL, there was no significant
difference in cumulative release between 1 and 8 mL/min. Also,
after 22.5 mL, the average wt % of release from 1 mL/min was
approximately an order of magnitude lower than the two other
tests.
Varying Fat Content
Figure 7 displays SB release for three milk fluids with fat con-
tents of 0.0, 2.9, and 4.2 wt % at a constant suction pulse rate
of 60 pulses/min and constant flow rate of 5 mL/min. Pulse am-
plitude and average vacuum pressure were also kept the same
for all flow rates. For 2.9 and 4.2 wt % fat fluids, there was
no statistical difference in either release concentrations or cu-
mulative release for the entire test. These two fluids also had
the same total protein content (1.7 wt %), suggesting that SB
release rate may not be influenced between these two fat com-
positions for the same protein content. At 0.0 wt % fat, a higher
release concentration in collected fractions was seen until the
majority of tablet had released (with posttest significance be-
tween 0 and 12 mL and 27 and 34.5 mL). Zero wt % fat also
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Figure 5. Effect of suction pulse rate on sulforhodamine B (SB) release. The effect of suction pulse rates of 120, 60, 30, and 0 (uniform flow)
pulses/min at a constant flow rate of 5 mL/min on SB release into human milk is compared. Data are displayed as the average for three repeat
tests of: (a) SB concentration in collected fractions and (b) cumulative SB release relative to amount in NSDS tablet. ANOVA analysis was
performed between the test conditions with significance at (*) p < 0.05, (**) p < 0.01, and (***) p < 0.001 indicated above the horizontal axis.
Error bars represent the standard error between repeat tests.
had a lower total protein content of 1.2 wt % as compared with
1.7 wt %. It is possible that a combination of both lower fat and
protein contents contributed to increased SB release rate.
DISCUSSION
Variation in Suction Pulse Rate
For these experiments, the same pressure cycle wasmaintained
throughout the experiments apart from 0 suction pulses/min
where the system was run at atmospheric pressure. The fact
that a suction pulse rate of 0 pulses/mL produced a significantly
lower release of SB than all other conditions provided clear evi-
dence that the vacuum pump’s (P3) cyclic action was the major
factor dictating SB release rather than the feed pump (P1) con-
trolling the same average flow rate for each pulse condition.
As discussed, in breastfeeding the infant has nonregular suc-
tion pattern behavior in a typical feed.27,28,32 For this study, in
order to more accurately determine the effect of a single vari-
able (the suction pulse rate), this more complex behavior was
not mimicked. It allowed the identification of higher pulse rates
appearing to correlate with increased cumulative release of SB.
The degree of variation in repeat tests suggests that a complex
interaction between the milk and the tablet may occur, with
small changes in tablet positioning potentially influencing re-
lease characteristics.
Varying Flow Rate
There were no clear trends in release characteristics to flow
rate, possibly because of competing factors controlling the
tablet disintegration and dissolution rates at different flow
rates. All three flow conditions had released at least 60% of
SB after 40 mL of milk. Upon inspection after the 1 mL/min
tests, a large amount of tablet was seen to be residing in the
upper half of the holder (stuck to the mesh). This indicated that
channels of fluid were likely passing predominantly below the
tablet creating a relatively slow release rate.
Varying Fat Content
The two fluids used to mimic breast milk (2.9 and 4.2 wt %
fat) in this set of experiments had statistically insignificant dif-
ferences in release patterns. This result suggests that the re-
ported variation in fat content during a typical breastfeed may
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Figure 6. Effect of flow rate on sulforhodamine B (SB) release. The effect of flow rates of 1, 5, and 8 mL/min at a constant suction pulse rate of
60 pulses/min on SB release into human milk is compared. Data are displayed as the average for three repeat tests of: (a) SB concentration in
collected fractions and (b) cumulative SB release relative to amount in NSDS tablet. ANOVA analysis was performed between the test conditions
with significance at (*) p < 0.05, (**) p < 0.01, and (***) p < 0.001 indicated above the horizontal axis. Error bars represent the standard error
between repeat tests.
not have a large influence upon tablet release properties.17,18
Also, as discussed, the average fat, protein, and lactose content
in feeds vary significantly within the first 30 days of life,21,24
and so fast release formulations will be needed to cater for this
variation of milk compositions.
Mimicking Infant Behavior During Lactation
For this study, the action of lactation induced by the vacuum
created by the infant was the sole consideration. The infant’s
tongue also plays a role in inducing the breastfeeding process,
with recent evidence suggesting its influence upon lactation
may be most prominent during the initial stages of inducing
lactation rather than during the actual breastfeed.27,34–36
Tablet Holder Considerations Within Nipple Shield
The design of a clinical NSDS to contain a tablet would likely
have it secured in place. Initial prototypes for this study used
a cross-hair holder to position the tablet within the center of
the nipple shield. However, it was found that milk channeled
around the tablet and less than 50 wt % would typically be
released when 100 mL of fluid passed through the device. On
the basis of this observation, a holder that allowed the tablet to
drop to the lowest point in any orientation in the holder is most
likely an effective manner of maximizing wettability of tablet
surface by milk in device use, increasing the likelihood of API
delivery.
Tablet Formulation
Cumulative release of SB for most test conditions did not reach
80% within 40 mL. Depending on the therapeutic ingredient to
be delivered, formulations will need to be designed to ensure
that at least the minimum acceptable dose is delivered within
the majority of breastfeeds, which have been reported to last
for approximately 80 g, but with high variation.18 The amount
of intended uses of the device per day will also have to be sig-
nificantly lower than the amount of feeds to ensure that the
minimum required dose is always met. A study of 71 breast-
feeding infants of 1–6 months found they feed on average 11
times a day. However, there are highly variable feeding lengths
and intervals dependent on the infant and the mother.18,35 Be-
cause of this variability, the NSDSmay be best suited for single
daily administration of substances that can have a relatively
wide range of acceptable doses, such as potentially probiotics.37
The basis of the formulation method and composition used in
this study may need to be revised to ensure faster delivery
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Figure 7. Effect of fat content on sulforhodamine B (SB) release. The effect of fluid compositions of 4.2, 2.9, and 0 wt % fat human milk at a
constant suction pulse rate of 60 pulses/min and flow rate of 5 mL/min is on SB release into the milk is compared. Data are displayed as the
average for three repeat tests of: (a) SB concentration in collected fractions and (b) cumulative SB release relative to amount in NSDS tablet.
ANOVA analysis was performed between the test conditions with significance at (*) p < 0.05, (*) p < 0.01, and (***) p < 0.001 indicated above
the horizontal axis. Error bars represent the standard error between repeat tests.
for clinical settings, although release rates may increase as
the full physiological process of breastfeeding using a NSDS is
mimicked in future studies. For example, during nipple shield
use, the tongue is likely to press against the underside of the
nipple shield, and depending on how the tablet is built into the
shield, this may promote tablet disintegration and delivery to
the infant.
Also, rather than using SB as a model compound, the use
of actual APIs with different physicochemical properties may
lead to different release characteristics for the otherwise same
formulation. Appropriate formulation development strategies
will be selected considering the physicochemical properties of
drugs (e.g., solubility) and intended drug release mechanism to
ensure the optimum use of the NSDS.
The similar release characteristics observed for different fat
contents (with constant protein content) may be specific to this
formulation and the milk composition used. Interestingly, pre-
vious tablet disintegration studies in relevant media have re-
ported that protein films coating tablets can slow disintegration
times, suggesting that differing protein contents in milk may
influence tablet disintegration in a NSDS.38
CONCLUSIONS
This proof of concept study identified physiological behaviors
within breastfeeding that could influence API release from a
NSDS. It was achieved using an apparatus designed to mimic
lactation from a human nipple induced purely by infant suction.
TheNSDSwould be used bymothers to deliver drugs and nutri-
ents to her infant during breastfeeding, with its use potentially
circumventing many problems that arise in current methods of
infant drug delivery, particularly in developing countries. The
simulation apparatus could be further developed to incorporate
the action of a breastfeeding infant’s tongue, to allow identifi-
cation of its influence on API release characteristics from a
NSDS. Using the lactation apparatus with a NSDS containing
a tablet, it was found that increased infant suction pulse rate
(for constant fluid content and constant average flow rate) cor-
related with increased cumulative release into milk of a model
compound contained within the tablet. Results also suggested
that the changing fat content during a breastfeed would not
significantly influence API release from the tablet for constant
suction conditions of an infant. These are essential findings
for use in optimizing relevant factors in NSDS tablet design,
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to ensure consistent and reproducible drug release within a
certain volume of a breastfeed.
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